Literature DB >> 2804897

Inflammatory symptoms in breast cancer. Correlations with growth rate, clinicopathologic variables, and evolution.

F Tabbane1, J Bahi, K Rahal, A el May, M Riahi, M Cammoun, M Hechiche, M Jaziri, N Mourali.   

Abstract

Based on two pretreatment evaluations, doubling time (DT) was calculated in 75 cases of invasive breast cancer (BC). The cases studied were more or less equally distributed between three DT groups: fast-growing tumors (DT less than 90 days), intermediate cases (DT between 90 and 180 days), and slow-growing tumors (DT greater than 180 days. A correlation was found to exist between DT and patient age and, to an even greater extent, between DT and pathologic prognostic indicators such as histologic grading and nuclear grade. Inflammatory symptoms were not associated with DT, but were closely related to the size of the tumor and regional lymph node involvement. The date of detection of distant metastases depended heavily on the DT of the BC:BC with shorter DT = earlier metastatic spread. The presence of inflammatory signs was also decisive: within each DT category, inflammatory BC metastases were both more frequent and precocious.

Entities:  

Mesh:

Year:  1989        PMID: 2804897     DOI: 10.1002/1097-0142(19891115)64:10<2081::aid-cncr2820641019>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Growth of Breast Cancer and Limited Surgery.

Authors: 
Journal:  Breast Cancer       Date:  1996-03-29       Impact factor: 4.239

2.  Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report.

Authors:  Yuji Yamashita; Yuko Tanaka; Seishi Kono; Meiko Nishimura; Toru Mukohara; Yukiko Morinaga; Shigeo Hara; Shintaro Takao
Journal:  Breast Care (Basel)       Date:  2017-02-28       Impact factor: 2.860

3.  Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy.

Authors:  Richard J Santen; Wei Yue; Daniel F Heitjan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-14       Impact factor: 4.254

4.  Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients.

Authors:  An-Chi Lo; Celina G Kleer; Mousumi Banerjee; Sherif Omar; Hussein Khaled; Saad Eissa; Ahmed Hablas; Julie A Douglas; Sharon H Alford; Sofia D Merajver; Amr S Soliman
Journal:  Breast Cancer Res Treat       Date:  2007-12-04       Impact factor: 4.872

5.  Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO).

Authors:  Meriem Slaoui; Abdou Azaque Zoure; Fatima Zahra Mouh; Youssef Bensouda; Mohammed El Mzibri; Youssef Bakri; Mariam Amrani
Journal:  BMC Cancer       Date:  2018-07-05       Impact factor: 4.430

6.  Detection of cancer before distant metastasis.

Authors:  Frank A W Coumans; Sabine Siesling; Leon W M M Terstappen
Journal:  BMC Cancer       Date:  2013-06-13       Impact factor: 4.430

7.  In Vivo Tumor Growth Rate Measured by US in Preoperative Period and Long Term Disease Outcome in Breast Cancer Patients.

Authors:  Tae-Kyung Yoo; Jun Won Min; Min Kyoon Kim; Eunshin Lee; Jongjin Kim; Han-Byoel Lee; Young Joon Kang; Yun-Gyoung Kim; Hyeong-Gon Moon; Woo Kyung Moon; Nariya Cho; Dong-Young Noh; Wonshik Han
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

8.  Has tumor doubling time in breast cancer changed over the past 80 years? A systematic review.

Authors:  Meryl Dahan; Delphine Hequet; Claire Bonneau; Xavier Paoletti; Roman Rouzier
Journal:  Cancer Med       Date:  2021-07-15       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.